Aminophylline Use in Asthma: Evidence Summary
Aminophylline should NOT be used routinely in acute asthma exacerbations, as it provides no additional bronchodilation beyond standard therapy with inhaled beta-2 agonists and corticosteroids, while significantly increasing adverse effects including vomiting and cardiac arrhythmias. 1, 2
Current Guideline Recommendations
Position in Treatment Algorithm
Sustained-release theophylline (oral aminophylline) is classified as alternative, NOT preferred therapy for mild persistent asthma (step 2 care) or as adjunctive therapy with inhaled corticosteroids in patients ≥5 years of age 3
Theophylline is considered a mild to moderate bronchodilator with possible mild anti-inflammatory effects, but requires mandatory serum concentration monitoring 3
First-line treatments remain: inhaled beta-2 selective agonists and systemically administered corticosteroids for acute exacerbations 1
Evidence for Acute Asthma Exacerbations
Emergency Department Setting
The FDA label explicitly states that most studies in emergency departments show intravenous aminophylline does NOT produce greater bronchodilation and increases the risk of adverse effects when added to inhaled beta-2 agonists and corticosteroids 1
The highest quality systematic review evidence demonstrates:
No reduction in hospital admissions (OR 0.58; 95% CI 0.30 to 1.12) when aminophylline is added to standard therapy 2
No improvement in peak expiratory flow at 12 hours (MD 8.30 L/min; 95% CI -20.69 to 37.29) or 24 hours (MD 22.20 L/min; 95% CI -56.65 to 101.05) 2
No relationship between baseline airflow limitation or corticosteroid use on aminophylline effectiveness 2
Hospitalized Patients with Severe Asthma
The FDA acknowledges that some studies show benefit in hospitalized patients not responding adequately to inhaled beta-2 agonists 1
This represents the ONLY potential indication where aminophylline might be considered, specifically:
- Patients requiring hospitalization
- Inadequate response to maximized inhaled bronchodilator therapy
- Already receiving systemic corticosteroids
Pediatric Population
In children over 2 years with severe acute asthma:
Aminophylline improves FEV1% predicted at 6-8,12-18, and 24 hours when added to steroids and beta-2 agonists 4
However, there is NO reduction in: symptoms, frequency of nebulizations, length of hospital stay, or mechanical ventilation rates 4
Three-fold increased risk of vomiting compared to placebo 4
Adverse Effects Profile
For every 100 patients treated with aminophylline, expect:
20 additional patients with vomiting (OR 4.21; 95% CI 2.20 to 8.07) 2
15 additional patients with palpitations/arrhythmias (OR 3.02; 95% CI 1.15 to 7.90) 2
No significant difference in tremor 2
Critical Monitoring Requirements
If aminophylline must be used, mandatory dose reduction and frequent serum concentration monitoring is required in:
- Neonates with decreased renal function 1
- Hepatic insufficiency (50%+ clearance reduction) 1
- Congestive heart failure (50%+ clearance reduction) 1
- Sustained fever ≥39°C for ≥24 hours 1
- Third trimester pregnancy, sepsis with multiorgan failure, hypothyroidism 1
Clearance is increased 50-80% in tobacco smokers, requiring dose adjustments 1
Clinical Decision Algorithm
Do NOT use aminophylline if:
- Patient is in emergency department with acute asthma
- Standard therapy (inhaled beta-2 agonists + corticosteroids) has not been maximized
- Patient has any contraindications or high-risk features for toxicity
Consider aminophylline ONLY if:
- Patient requires hospitalization for severe asthma
- Inadequate response to maximized inhaled beta-2 agonists
- Already receiving systemic corticosteroids
- No contraindications present
- Ability to monitor serum concentrations is available
The risk-benefit balance of intravenous aminophylline is unfavorable in most clinical scenarios 2